Note 6 - Intangibles, Net

9 Months Ended

Sep. 30, 2025

Notes to Financial Statements

Intangible Assets Disclosure [Text Block]

NOTE 6 – INTANGIBLES, NET

The Company’s intangibles, net consisted of the following:

	As of September 30, 2025							As of December 31, 2024
	Gross Carrying Costs		Accumulated Amortization			Net Carrying Amount		Gross Carrying Costs		Accumulated Amortization			Net Carrying Amount
Patents & Trademarks	$	64,087		(16,565	)		47,522	$	64,087	$	(13,132	)	$	50,955

Finite-lived intangible assets are amortized over their estimated useful lives. Amortization expense, recorded within general and administrative expenses of continuing operations, was $1,144 and $1,246 during the three months ended September 30, 2025 and 2024, respectively, and $3,433 and $3,737 during the nine months ended September 30, 2025 and 2024, respectively.

The following table outlines the estimated future amortization expense related to intangible assets held as of September 30, 2025:

Year Ending December 31,
Remainder of 2025	$	1,144
2026		4,578
2027		4,578
2028		4,578
2029		4,578
Thereafter		28,066
Total	$	47,522

The Company reviews finite-lived intangible assets for impairment in accordance with ASC 360, Property, Plant, and Equipment whenever events or changes in circumstances indicate the carrying amount may not be recoverable. Events or changes in circumstances that indicate the carrying amount may not be recoverable include, but are not limited to, a significant change in the medical device marketplace and a significant adverse change in the business climate in which the Company operates. No impairment charges related to finite-lived intangible assets were incurred during the nine months ended September 30, 2025 and 2024.